<abstract xmlns="http://www.w3.org/1999/xhtml"><p> The ageing process in the European society will become one of the key driving forces of change over the next decades. The specific demands of older generations constitute a key market of the future, and the pressure to improve and expand health services increases, especially as far as chronic diseases, such as cancer. Availability of cost effective cancer early detection protocols, based on predictive biomarkers, will improve patients management reducing consequently the high costs associated to treating patients when the disease is at an advanced stage.</p></abstract>

The ageing process in the European society will become one of the key driving forces of change over the next decades. The specific demands of older generations constitute a key market of the future, and the pressure to improve and expand health services increases, especially as far as chronic diseases, such as cancer. Availability of cost effective cancer early detection protocols, based on predictive biomarkers, will improve patients management reducing consequently the high costs associated to treating patients when the disease is at an advanced stage.

Biomarkers development for early detection of cancer: Reducing the burden of cancer in the ageing society

The EuroBiotech Journal

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

The ageing process in the European society will become one of the key driving forces of change over the next decades. The specific demands of older generations...

SCCA-IgM	DB 1	DB 2	DB 3	DB 4	DB 5	DB 6	TOT
≥0 AU/mL	272 100%	127 100%	67 100%	76 100%	24 100%	31 100%	597 100%
>50 AU/mL	206 76%	106 84%	61 91%	32 42%	22 92%	31 100%	458 77%
>200 AU/mL	121 44%	52 41%	29 43%	51 67%	7 29%	18 58%	278 47%
>300 AU/mL	88 32%	37 29%	20 30%	34 45%	7 29%	10 32%	196 33%
>500 AU/mL	67 25%	24 19%	16 24%	19 25%	5 21%	2 7%	133 22%
>600 AU/mL	60 22%	18 14%	13 19%	13 17%	3 13%	2 7%	109 18%

Annual cost of US only every 6 months	€46.516.400
Annual cost of SCCA-IgM analysis	€4.008.069
Costs saved by doing 1 US/year instead of 2	€5.247.488
Net costs of SCCA-IgM+US/year	€45.276.981
Annual saving of SCCA-IgM+US vs. US only	€1.239.419
HCC identified/year	€11.974
Cost of US only/HCC identified	€3.885
Cost of SCCA-IgM+US/HCC identified	€3.781
Saving/HCC identified	€104

SCCA-IgM	HCC 12 months %	HCC 6 months %	HCC 4 months %
≤50 AU/mL	0/16 0%	0/16 0%	0/16 0%
>50 AU/mL	24/287 8,4%	11/287 3,8%	10/287 3,5%
>500 AU/mL	7/63 11,1%	5/63 7,9%	5/63 7,9%

Biomarkers development for early detection of cancer: Reducing the burden of cancer in the ageing society

Article Category: Review

Published Online: Feb 06, 2018

Page range: 30 - 34

DOI: https://doi.org/10.2478/ebtj-2018-0005

Keywords
biomarkers, cancer, health technology assessment (HTA), hepatocellular carcinoma, chronic hepatitis C, cirrhosis

© 2018 Laura Paneghetti, Andrea Gallotta, Chiara Parrozzani, Giorgio Fassina, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Figure 1

SCCA-IgM serological levels in patients with HCV infection and cirrhosis

number of HCC and relative costs and savings associated with the monitoring of HCV-cirrhotic patients in Italy.

SCCA-IgM levels and timing of HCC development in patients with HCV infection and cirrhosis

Biomarkers development for early detection of cancer: Reducing the burden of cancer in the ageing society

Article Category: Review

Published Online: Feb 06, 2018

Page range: 30 - 34

DOI: https://doi.org/10.2478/ebtj-2018-0005

Keywordsbiomarkers, cancer, health technology assessment (HTA), hepatocellular carcinoma, chronic hepatitis C, cirrhosis

© 2018 Laura Paneghetti, Andrea Gallotta, Chiara Parrozzani, Giorgio Fassina, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Figure 1

SCCA-IgM serological levels in patients with HCV infection and cirrhosis

number of HCC and relative costs and savings associated with the monitoring of HCV-cirrhotic patients in Italy.

SCCA-IgM levels and timing of HCC development in patients with HCV infection and cirrhosis

Keywords
biomarkers, cancer, health technology assessment (HTA), hepatocellular carcinoma, chronic hepatitis C, cirrhosis